» Articles » PMID: 17027423

Recommendations for Reporting Randomized Controlled Trials of Herbal Interventions: Explanation and Elaboration

Overview
Publisher Elsevier
Specialty Public Health
Date 2006 Oct 10
PMID 17027423
Citations 65
Authors
Affiliations
Soon will be listed here.
Abstract

Controlled trials that use randomized allocation are the best tool to control for bias and confounding in trials testing clinical interventions. Investigators must be sure to include information that is required by the reader to judge the validity and implications of the findings in the reports of these trials. In part, complete reporting of trials will allow clinicians to modify their clinical practice to reflect current evidence toward the improvement of clinical outcomes. The consolidated standards of reporting trials (CONSORT) statement was developed to assist investigators, authors, reviewers, and editors on the necessary information to be included in reports of controlled clinical trials. The CONSORT statement is applicable to any intervention, including herbal medicinal products. Controlled trials of herbal interventions do not adequately report the information suggested in CONSORT. Recently, reporting recommendations were developed in which several CONSORT items were elaborated to become relevant and complete for randomized controlled trials of herbal medicines. We expect that these recommendations will lead to more complete and accurate reporting of herbal trials. We wrote this explanatory document to outline the rationale for each recommendation and to assist authors in using them by providing the CONSORT items and the associated elaboration, together with examples of good reporting and empirical evidence, where available, for each. These recommendations for the reporting of herbal medicinal products presented here are open to revision as more evidence accumulates and critical comments are collected.

Citing Articles

Citrus supplementation in subjective cognitive decline: results of a 36-week, randomized, placebo-controlled trial.

Galluzzi S, Marizzoni M, Gatti E, Bonfiglio N, Cattaneo A, Epifano F Nutr J. 2024; 23(1):135.

PMID: 39482712 PMC: 11529263. DOI: 10.1186/s12937-024-01039-8.


Reporting quality and risk of bias of randomized controlled trials of Chinese herbal medicine for multiple sclerosis.

Wu J, Yang J, Hu J, Xu S, Zhang X, Qian S Front Immunol. 2024; 15:1429895.

PMID: 39229262 PMC: 11369894. DOI: 10.3389/fimmu.2024.1429895.


Reporting characteristics and quality of randomized controlled trial protocols in traditional Chinese medicine: a cross-sectional study.

Zhang L, Li H, Hu L, Ou X, Tan H, Zhang X Front Pharmacol. 2024; 15:1389808.

PMID: 38910893 PMC: 11190156. DOI: 10.3389/fphar.2024.1389808.


Medicinal plants for allergic rhinitis: A systematic review and meta-analysis.

Lim X, Lau M, Zolkifli N, Sastu Zakaria U, Mohd Rahim N, Lai N PLoS One. 2024; 19(4):e0297839.

PMID: 38603736 PMC: 11008904. DOI: 10.1371/journal.pone.0297839.


Editorial: Clinical phytopharmacology.

Willcox M, Tai C, Chattopadhyay K, Hu X, Heinrich M Front Pharmacol. 2024; 14:1353483.

PMID: 38288085 PMC: 10822887. DOI: 10.3389/fphar.2023.1353483.